Glutathione (GSH) vs MOTS-c
Both Glutathione (GSH) and MOTS-c are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.
Glutathione (GSH)
Evidence BReduced L-Glutathione
Technically a tripeptide (γ-glutamyl-cysteinyl-glycine) and the body's primary antioxidant. Often grouped with peptide therapy in IV/compounded form for liver support and oxidative stress.
View full Glutathione (GSH) profile →MOTS-c
Evidence BMitochondrial-derived peptide MOTS-c
A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.
View full MOTS-c profile →Side-by-Side
| Attribute | Glutathione (GSH) | MOTS-c |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved as therapeutic — sold as supplement; intravenous use compounded | Not FDA-approved — research peptide; multiple early-phase clinical trials |
| Typical Dose | 200–600 mg sublingual / 600–2400 mg IV (compounded) | 5–10 mg, 2–3 times weekly (subcutaneous) |
| Clinics Indexed | 312 | 22 |
| Categories | antioxidant, longevity | metabolic, longevity |
Key reported benefits — Glutathione (GSH)
- ✓Master antioxidant
- ✓Liver detoxification support
- ✓Oxidative stress reduction
Key reported benefits — MOTS-c
- ✓Insulin sensitivity
- ✓Exercise capacity
- ✓Metabolic flexibility
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.